Monte Rosa Therapeutics (NASDAQ:GLUE) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Monte Rosa Therapeutics (NASDAQ:GLUE) from a hold rating to a sell rating in a research report released on Saturday morning.

Several other equities analysts have also recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and set a $31.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.80.

Monte Rosa Therapeutics Trading Down 2.7%

Monte Rosa Therapeutics stock opened at $15.63 on Friday. The firm has a market cap of $1.25 billion, a P/E ratio of -33.98 and a beta of 1.63. Monte Rosa Therapeutics has a 1-year low of $3.50 and a 1-year high of $25.77. The firm has a 50-day moving average of $19.62 and a 200-day moving average of $14.91.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The business had revenue of $2.78 million for the quarter, compared to analysts’ expectations of $17.09 million. Monte Rosa Therapeutics had a negative net margin of 31.23% and a negative return on equity of 15.12%. Research analysts forecast that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the transaction, the chief executive officer owned 613,471 shares in the company, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the completion of the sale, the insider directly owned 22,693 shares in the company, valued at $410,743.30. This trade represents a 52.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,771 shares of company stock worth $693,692 in the last 90 days. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in Monte Rosa Therapeutics by 10.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock worth $80,265,000 after purchasing an additional 481,844 shares in the last quarter. Vanguard Group Inc. increased its stake in Monte Rosa Therapeutics by 8.6% during the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after purchasing an additional 257,547 shares in the last quarter. State Street Corp increased its stake in Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares in the last quarter. AQR Capital Management LLC raised its holdings in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after buying an additional 1,054,406 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after buying an additional 53,278 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.